Hepatitis C, the new, pricey drug for hepatitis infection created quite a ripple in the US drug market in 2014, with the overall spending escalating to 13% more since last year taking up the figure to a record $374 billion. The industry reports by the IMS Institute for Healthcare Informatics indicate that more than $11 billion was spent on the new hepatitis C prescription drug.
The industry research firm analyzes the top-selling drugs, trends and sales in the pharmaceutical industry and annually provides a complete report on these findings. Surprisingly the amount spent on the new drug was much more as compared to the $1 billion spent on the new health insurance under the Affordable Care Act.
According to Michael Kleinrock, the director of IMS Health research development, this has been the highest earning in one year ever recorded and is certainly a huge amount of spending. The main reason behind this sudden increase in the demand for hepatitis C drug is that the drug is being considered the breakthrough treatment for this particular disease.
Is Hepatitis C Dangerous?
A contagious form of liver disease, hepatitis C can range in between mild illness to severe infection and can last in between a few weeks to lifelong. The infection is caused due to the hepatitis C virus (HCV) which spreads when a person is exposed to the blood of an infected patient. Depending upon the symptoms hepatitis C can be chronic or acute.
Chronic type of hepatitis C is dangerous to health and can cause long-term problems for the health such as liver failure, liver damage, and liver cancer and in certain cases death. It is known as the leading cause of liver cancer and cirrhosis and one of the main reasons necessitating liver transplantations in the United States. Every year, more than 15,000 people succumb to this infection in America.
This life-threatening nature of hepatitis C is the main reason behind the increased sale of the newly prescribed hepatitis C drug.